The HER family of receptors, EGFR/HER1, HER2, HER3, and HER4 are rational targets for anti-cancer drugs because they activate complex signal transduction pathways that lead to tumor cell proliferation, survival, and metastasis [69]. This evidence concerns the gene ERBB4 and neoplasm.